tetano
Editor, Senior Moderator
J Virol. 2013 May 29. [Epub ahead of print]
Protection against lethal influenza with a viral mimic.
Baker SF, Guo H, Albrecht RA, Garc?a-Sastre A, Topham DJ, Mart?nez-Sobrido L.
Source
Department of Microbiology and Immunology.
Abstract
Despite countermeasures against influenza virus that prevent (vaccines) and treat (antivirals) infection, this upper respiratory human pathogen remains a global health burden, causing both seasonal epidemics and occasional pandemics. More potent and safe new vaccine technologies would contribute significantly to the battle against influenza and other respiratory infections. Using plasmid-based reverse genetics techniques, we have developed a single-cycle infectious Influenza Virus (sciIV) with immunoprotective potential. In our sciIV approach, the fourth viral segment, which encodes for the receptor-binding and fusion protein hemagglutinin (HA), has been removed. Thus upon infection of normal cells, although no infectious progeny are produced, the expression of other viral proteins occurs and is immunogenic. Consequently, sciIV is protective against influenza homologous and heterologous viral challenges in a mouse model. Vaccination with sciIV protects in a dose- and replication-dependent manner, which is attributed to both humoral responses and T cells. Safety, immunogenicity and protection conferred by sciIV vaccination were also demonstrated in ferrets, where this immunization additionally blocked direct and aerosol transmission events. Altogether, our studies suggest that sciIV may have potential as a broadly protective vaccine against influenza virus.
PMID:
23720727
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23720727
Protection against lethal influenza with a viral mimic.
Baker SF, Guo H, Albrecht RA, Garc?a-Sastre A, Topham DJ, Mart?nez-Sobrido L.
Source
Department of Microbiology and Immunology.
Abstract
Despite countermeasures against influenza virus that prevent (vaccines) and treat (antivirals) infection, this upper respiratory human pathogen remains a global health burden, causing both seasonal epidemics and occasional pandemics. More potent and safe new vaccine technologies would contribute significantly to the battle against influenza and other respiratory infections. Using plasmid-based reverse genetics techniques, we have developed a single-cycle infectious Influenza Virus (sciIV) with immunoprotective potential. In our sciIV approach, the fourth viral segment, which encodes for the receptor-binding and fusion protein hemagglutinin (HA), has been removed. Thus upon infection of normal cells, although no infectious progeny are produced, the expression of other viral proteins occurs and is immunogenic. Consequently, sciIV is protective against influenza homologous and heterologous viral challenges in a mouse model. Vaccination with sciIV protects in a dose- and replication-dependent manner, which is attributed to both humoral responses and T cells. Safety, immunogenicity and protection conferred by sciIV vaccination were also demonstrated in ferrets, where this immunization additionally blocked direct and aerosol transmission events. Altogether, our studies suggest that sciIV may have potential as a broadly protective vaccine against influenza virus.
PMID:
23720727
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23720727